logo

For the Inventor, By the Inventor

Bochum, Germany

Michael Dorschug

This inventor holds 7 USPTO granted patents. Top assignee: Hoechst Aktiengesellschaft. Active years: 1991-2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael Dorschug. Retrieved from https://idiyas.com/inventor/michael-dorschug

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 7

% Patents Active = 100.0

Average Co-Inventor Count = 1.5

ph-index = 6

Forward Citations = 250(Granted Patents)


Company Filing History:

goldMedal7 out of 6,705 
 
Hoechst Aktiengesellschaft
 patents

Years Active: 1991-2000

Loading Chart...
7 patents (USPTO):Explore Patents
1. 6100376 - A.sup.21, B.sup.30, modified insulin derivatives having an altered (2000-08-08),
2. 5728543 - Clostripain catalyzed hydrolysis of preproinsulin analogs into (1998-03-17),
3. 5656722 - A.sup.21 -, B.sup.30 - modified insulin derivatives having an altered (1997-08-12),
4. 5270176 - Method for the selective cleavage of fusion proteins with lysostaphin (1993-12-14),
5. 5177058 - Pharmaceutical formulation for the treatment of diabetes mellitus (1993-01-05),
6. 5101013 - Process for isolating basic proteins from protein mixtures (1992-03-31),
7. 5028587 - Mixed crystals of insulin and insulin derivatives (1991-07-02),

Title: The Innovative Contributions of Michael Dorschug

Introduction

Michael Dorschug is a notable inventor based in Bochum, Germany. He has made significant contributions to the field of diabetes treatment through his innovative work on insulin derivatives. With a total of 7 patents to his name, Dorschug continues to push the boundaries of medical science.

Latest Patents

Among his latest patents are A.sup.21 and B.sup.30, which focus on modified insulin derivatives. These derivatives have an altered structure that provides improved stability in weakly acidic aqueous mediums. They also feature a special action profile, making them particularly effective for the treatment of diabetes mellitus. Additionally, he has developed a process for the specific hydrolysis of preproinsulin analogs, utilizing clostripain and, if necessary, carboxypeptidase B to yield the corresponding insulins.

Career Highlights

Dorschug is currently associated with Hoechst Aktiengesellschaft, a company known for its advancements in pharmaceuticals and biotechnology. His work has been instrumental in developing new therapeutic options for diabetes patients, showcasing his commitment to improving healthcare outcomes.

Collaborations

Throughout his career, Dorschug has collaborated with esteemed colleagues such as Gerhard Seipke and Ranier Obermeier. These partnerships have fostered a collaborative environment that enhances innovation and research in the field.

Conclusion

Michael Dorschug's contributions to the field of diabetes treatment through his innovative patents and collaborations highlight his importance as an inventor. His work continues to pave the way for advancements in medical science, ultimately benefiting patients worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…